Standard Life Aberdeen plc boosted its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 4.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,652,325 shares of the company’s stock after purchasing an additional 69,272 shares during the quarter. Standard Life Aberdeen plc owned about 0.15% of Eli Lilly And Co worth $141,000,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Global X Management Co. LLC increased its holdings in Eli Lilly And Co by 10.6% during the 1st quarter. Global X Management Co. LLC now owns 20,268 shares of the company’s stock worth $1,568,000 after purchasing an additional 1,945 shares in the last quarter. HL Financial Services LLC increased its holdings in Eli Lilly And Co by 3.8% during the 1st quarter. HL Financial Services LLC now owns 82,453 shares of the company’s stock worth $6,379,000 after purchasing an additional 2,986 shares in the last quarter. Hennessy Advisors Inc. bought a new position in Eli Lilly And Co during the 1st quarter worth about $5,532,000. Daiwa Securities Group Inc. grew its holdings in shares of Eli Lilly And Co by 3.7% in the 1st quarter. Daiwa Securities Group Inc. now owns 46,417 shares of the company’s stock valued at $3,591,000 after acquiring an additional 1,644 shares in the last quarter. Finally, Meag Munich Ergo Kapitalanlagegesellschaft MBH grew its holdings in shares of Eli Lilly And Co by 22.5% in the 1st quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 149,835 shares of the company’s stock valued at $11,490,000 after acquiring an additional 27,533 shares in the last quarter. 76.55% of the stock is currently owned by institutional investors.

Eli Lilly And Co stock traded down $0.81 during midday trading on Friday, reaching $105.77. 3,071,883 shares of the company’s stock were exchanged, compared to its average volume of 2,944,340. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $107.84. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. The stock has a market capitalization of $113.81 billion, a P/E ratio of 24.71, a PEG ratio of 1.76 and a beta of 0.28.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. During the same quarter last year, the company posted $1.11 earnings per share. Eli Lilly And Co’s quarterly revenue was up 9.1% on a year-over-year basis. research analysts forecast that Eli Lilly And Co will post 5.47 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, September 10th. Investors of record on Wednesday, August 15th were issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a yield of 2.13%. The ex-dividend date of this dividend was Tuesday, August 14th. Eli Lilly And Co’s payout ratio is currently 52.57%.

Several brokerages have recently weighed in on LLY. DZ Bank restated a “hold” rating on shares of Eli Lilly And Co in a report on Friday, June 22nd. Cantor Fitzgerald set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, July 24th. Credit Suisse Group set a $84.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a report on Friday, July 13th. Jefferies Financial Group set a $100.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Sunday, July 15th. Finally, Barclays raised their price objective on Eli Lilly And Co from $98.00 to $107.00 and gave the company an “overweight” rating in a report on Friday, September 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company. Eli Lilly And Co currently has an average rating of “Buy” and an average target price of $100.69.

In other Eli Lilly And Co news, major shareholder Eli & Co Lilly sold 10,059 shares of the firm’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $14.83, for a total transaction of $149,174.97. Following the completion of the sale, the insider now directly owns 3,894,318 shares in the company, valued at $57,752,735.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $106.76, for a total transaction of $19,216,800.00. Following the sale, the insider now owns 119,832,753 shares of the company’s stock, valued at $12,793,344,710.28. The disclosure for this sale can be found here. Insiders have sold 1,685,070 shares of company stock valued at $167,108,944 in the last quarter. 0.11% of the stock is currently owned by corporate insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: How to calculate the intrinsic value of a stock

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.